

For the information of shareholders/investors, we are furnishing the following information pertaining to Suven Pharmaceuticals Limited (Resulting Company pursuant to Scheme of Arrangement (Demerger) as sanctioned by Hon'ble NCLT, Hyderabad Bench)

The Board of Directors of Suven Pharmaceuticals Limited in its meeting held today i.e. 13th February, 2020 approved the following matters:

- a) Considered the attached Un-Audited Standalone and Consolidated Financial Results (Post Demerger) of Suven Pharmaceuticals Ltd for the 3rd Quarter ended 31st December, 2019
- b) Limited Review Reports of Statutory Auditors of the Company on the financial results as mentioned above and
- c) The Board has declared an Interim Dividend of Rs 2.50 per equity share and a onetime special dividend of Rs 2.50 per equity share of Rs 1/- each totaling to Rs 5.00 per share to the shareholders (allottees pursuant to scheme of arrangement approved by the NCLT) of Suven Pharmaceuticals Limited. The interim dividend will be paid within the stipulated time under law.

Please find attached New Release and Investor Communication of our company.

Thanking you,
Yours faithfully,
For Suven Pharmaceuticals Limited

A handwritten signature in black ink, appearing to read "K. Hanumantha Rao".

K. Hanumantha Rao
Company Secretary

Encl: as above

Place: Hyderabad
Date: February 13, 2020

Suven Pharmaceuticals Limited



SUVEN PHARMACEUTICALS LTD

Regd. Off: 3rd Floor ,SDE Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

STATEMENT OF UN-AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & 9 MONTHS PERIOD ENDED 31st Dec ' 2019.

(Rs. In Lakhs)

PART - I		STANDALONE					
Sl. No.	PARTICULARS	For the Quarter Ended			For the 9 months period ended		For the year Ended
		31/12/2019	30/09/2019	31/12/2018	31/12/2019	31/12/2018	31/03/2019
		un- Audited	Audited	Un-Audited	un- Audited	Un-Audited	Audited
		(1)	(2)	(3)	(4)	(5)**	(6)**
1	Income						
	Revenue from operations	17,870.62	27,292.76	12,691.52	64,902.52	12,691.52	37,783.46
	Other Income	488.75	544.52	18.57	1,277.73	18.57	60.01
	Total income	18,359.37	27,837.28	12,710.09	66,180.25	12,710.09	37,843.47
2	Expenses						
	a) Cost of materials consumed	5,686.20	6,047.63	6,217.04	17,600.14	6,217.04	12,452.12
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,303.88)	3,057.82	(3,434.32)	21.80	(3,434.32)	(2,132.13)
	d) Employee benefits expense	1,756.68	1,742.23	1,335.38	5,420.05	1,335.38	2,963.15
	e) Finance costs	717.56	399.11	104.58	1,460.89	104.58	278.92
	f) Depreciation and amortisation expense	559.94	562.29	554.01	1,680.67	554.01	1,149.68
	g) Manufacturing Exps	2,707.32	2,680.40	2,657.37	7,931.62	2,657.37	5,130.47
	h) R & D Exps	-	-	-	-	-	-
	i) Other Expenses	1,058.35	1,207.28	961.95	3,150.02	961.95	2,214.55
	Total expenses	11,182.17	15,696.76	8,396.01	37,265.19	8,396.01	22,056.76
3	Profit before exceptional items & Tax (1-2)	7,177.20	12,140.52	4,314.08	28,915.06	4,314.08	15,786.71
4	Exceptional Items	-	-	-	-	-	-
5	Profit before Tax (3-4)	7,177.20	12,140.52	4,314.08	28,915.06	4,314.08	15,786.71
6	Tax Expenses						
	a) Current tax	1,962.27	3,140.18	880.26	7,531.87	880.26	3,317.07
	b) Deferred tax	15.08	8.76	(11.31)	(300.76)	(11.31)	1,542.21
7	Net Profit/ (Loss) for the period/year(5-6)	5,199.85	8,991.58	3,445.13	21,683.95	3,445.13	10,927.43
8	Other Comprehensive Income						
8.a	(i) Items that will not be reclassified to profit or loss	(82.35)	(4.23)	-	(90.81)	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	19.90	1.48	-	22.86	-	-
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	(62.45)	(2.75)	-	(67.95)	-	-
9	Total Comprehensive Income for the period (7+8)	5,137.40	8,988.83	3,445.13	21,616.00	3,445.13	10,927.43
10	Paid-up equity share capital	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
11	Other Equity	-	-	-	-	-	57,756.22
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :						
	a) Basic	4.09	7.06	2.71	17.04	2.71	8.59
	b) Diluted	4.09	7.06	2.71	17.04	2.71	8.59
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)



PART - II		(Rs. In Lakhs)					
		CONSOLIDATED					
Sl. No.	PARTICULARS	For the Quarter Ended			For the 9 months period ended		For the year Ended
		31/12/2019	30/09/2019	31/12/2018	31/12/2019	31/12/2018	31/03/2019
		un- Audited	Audited	Un-Audited	un- Audited	Un-Audited	Audited
		(1)	(2)	(3)	(4)	(5)**	(6)**
1	Income						
	Revenue from operations	17,870.62	27,292.76	12,691.52	64,902.52	12,691.52	37,783.46
	Other Income	488.75	544.52	18.57	1,277.73	18.57	60.01
	Total income	18,359.37	27,837.28	12,710.09	66,180.25	12,710.09	37,843.47
2	Expenses						
	a) Cost of materials consumed	5,686.20	6,047.63	6,217.04	17,600.14	6,217.04	12,452.12
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress	(1,303.88)	3,057.82	(3,434.32)	21.80	(3,434.32)	(2,132.13)
	d) Employee benefits expense	1,756.68	1,742.23	1,335.38	5,420.05	1,335.38	2,963.15
	e) Finance costs	760.55	442.40	104.58	1,584.85	104.58	278.92
	f) Depreciation and amortisation	559.94	562.29	554.01	1,680.67	554.01	1,149.68
	g) Manufacturing Exps	2,707.32	2,680.40	2,657.37	7,931.62	2,657.37	5,130.47
	h) R & D Exps	-	-	-	-	-	-
	i) Other Expenses	1,059.75	1,207.28	961.95	3,152.45	961.95	2,214.55
	Total expenses	11,226.56	15,740.05	8,396.01	37,391.58	8,396.01	22,056.76
3	Profit before exceptional items , Tax & share in profit/(Loss) of Associates (1-2)	7,132.81	12,097.23	4,314.08	28,788.67	4,314.08	15,786.71
4	Add : Share of profit/(Loss) of Associates.	635.58	352.19		2,724.38		
5	Profit before exceptional items , Tax (3+4)	7,768.39	12,449.42	4,314.08	31,513.05	4,314.08	15,786.71
6	Exceptional Items	-	-	-	-	-	-
7	Profit before Tax (5-6)	7,768.39	12,449.42	4,314.08	31,513.05	4,314.08	15,786.71
8	Tax Expenses						
	a) Current tax	1,962.27	3,140.18	880.26	7,531.87	880.26	3,317.07
	b) Deferred tax	15.08	8.76	(11.31)	(300.76)	(11.31)	1,542.21
9	Net Profit/ (Loss) for the period/year(7-8)	5,791.04	9,300.48	3,445.13	24,281.94	3,445.13	10,927.43
10	Other Comprehensive Income						
10.a	(i) Items that will not be reclassified to profit or loss	(82.35)	(4.23)	-	(90.81)	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	19.90	1.48	-	22.86	-	-
10.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	(62.45)	(2.75)	-	(67.95)	-	-
11	Total Comprehensive Income for the period (9 + 10)	5,728.59	9,297.73	3,445.13	24,213.99	3,445.13	10,927.43
12	Paid-up equity share capital Face Value of the Share	1,272.82 Re. 1.00	1,272.82 Re. 1.00	1,272.82 Re. 1.00	1,272.82 Re. 1.00	1,272.82 Re. 1.00	1,272.82 Re. 1.00
13	Other Equity	-	-	-	-	-	57,756.22
14	Earning Per Share (EPS) (Face value of Rs.1/- each) :						
	a) Basic	4.55	7.31	2.71	19.08	2.71	8.59
	b) Diluted	4.55	7.31	2.71	19.08	2.71	8.59
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)



NOTES:-1) The above results were reviewed by Audit Committee of the Board and approved by the Board of Directors' at their Meeting held on 13th Feb,2020 and the same has been reviewed by the Statutory Auditors.

2) This is the first financial results of the Company published in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter and nine months ended 31st December,2019 (pending for listing of 127,282,478 fully paid equity shares of Rs. 1 each of the Company on BSE Limited (BSE) and National Stock Exchange of India (NSE)). The aforesaid shares were allotted at par in terms of the Composite Scheme of Arrangement ('the Scheme') on 27th January, 2020 for an aggregated sum of Rs. 1,272.82 Lakhs, earlier credited to equity share suspense and since then transferred to equity share capital.

3) Consequent to the demerger of Demerged Undertaking of the erstwhile Suven Life Sciences Limited as a going concern into the Company, pursuant to the Scheme effective from appointed date being 1st October,2018, the financial results for the nine months ended 31st December,2019 are not comparable with the previous corresponding period. Further, for the purpose of calculating earnings per share for the year ended 31st March,2019, the equity shares issued pursuant to the Scheme have been considered effective as on 1st October,2018 and the equity shares of the Company outstanding stand cancelled from the aforesaid date.

4)** The figures for the year ended 31st March,2019 and Period ended 31st December ,2018 represent figures from 1st October,2018(Appointed date of demerger of Demerged Undertaking into the

5) The Company is engaged in the business of Pharmaceuticals Manufacturing & Services . Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.

6) The Company elected to exercise the option permitted u/s 115BAA of the Income tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019. Accordingly, the Company has recognised Provision for Income Tax for the nine months ended December 31, 2019 and re-measured its Deferred Tax Liability on the basis of the rate prescribed in the said section. The full impact of this change has been recognised in the Statement of Profit & Loss for the Period ended December 31, 2019.

7) The above is an extract of the detailed format of Quarterly/ Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quaterly/Annual Financial Results are available on the websites of the stock exchanges(s) and the listed entity. (www.bseindia.com and www.nseindia.com) and company's website www.suven.com .

8) As the company has invested in Suven Pharma Inc(WOS) during April,2019, the consolidated figures for the Qtr&period ended 31/12/2019&year ended 31/03/2019 are same as standalone .

9) The Board has declared an Interim Dividend of Rs.2.50 per equity share (250% of face value of Rs. 1.00/- each)and a one time special dividend of Rs.2.50(250% of face value of Rs.1.00 each) totalling to Rs.5.00 per share (500% of face value of Rs.1.00 each) post demerger of Suven's Pharmaceuticals mfg & Services business for the financial year 2019-20.

10) The corresponding previous period figures have been regrouped / reclassified where ever necessary.

Place : Hyderabad
Date : 13th Feb ' 2020



For SUVEN PHARMACEUTICALS LTD

Venkat Jasti

VENKAT JASTI

Chairman & MD

DIN: 00278028



Ref No.LR/SLSL/003/2019-20

Independent Auditor's Review Report on Unaudited Quarterly and Year to date Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

The Board of Directors of
SUVEN PHARMACEUTICALS LIMITED


We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **SUVEN PHARMACEUTICALS LIMITED**, having registered office at 3rd Floor, SDE Serene Chambers, Road No:5, Banjara Hills, Hyderabad-500034, Telangana for the quarter ended December 31, 2019 and year to date results for the period from April 01, 2019 to December 31, 2019 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Regulation) as amended, read with SEBI Circular No. CIR/CFD/CMD1/80/2019 dated July 19, 2019 ('the Circular').

This Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit, accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **KARVY & CO**
Chartered Accountants
(Firm Registration No.001757S)


(AJAYKUMAR KOSARAJU)
P A R T N E R
M.No.021989
UDIN: 20021989AAAABJ7596



Place: Hyderabad
Date: February 13, 2020



Ref No.LR/SLSL/004/2019-20

Independent Auditor's Review Report on the Unaudited Quarterly and Year to date Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To
The Board of Directors of
SUVEN PHARMACEUTICALS LIMITED

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of SUVEN PHARMACEUTICALS LIMITED ("the Parent") , subsidiary and its associate (the Parent, subsidiary and its associate together referred to as "the Group") for the quarter ended December 31, 2019 and year to date results for the period from April 01,2019 to December 31, 2019 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the Regulation'), read with SEBI Circular No. CIR/CFD/CMD1/80/2019 dated July 19, 2019 ('the Circular').
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, ("Ind AS 34") 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the Results of the following Entities:

Name of the Company	Relationship
Suven Pharma Inc	Wholly Owned Subsidiary
Rising Pharma Holdings Inc	Associate




13/02/2020

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of branch auditor and other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the Listing Regulations, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial information/ financial results of subsidiary included in the consolidated unaudited financial results, whose interim financial information/ financial results reflect total assets of Rs.24,600.44 lakhs as at 31st December 2019, total revenue of Rs.-Nil- ,total expenses of Rs.126.39 lakhs and total net loss after tax of Rs.126.39 lakhs for the period ended 31st December 2019, as considered in the consolidated unaudited financial results. The consolidated unaudited financial results also include the Group's share of net profit after tax of Rs.2,724.38 lakhs for nine months ended December 31, 2019, as considered in the consolidated unaudited financial results, in respect of associate, whose interim financial information/ financial results have not been reviewed by us. These interim financial information/ financial results have been reviewed by other auditors, whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary and associate, is based solely on the report of the other auditors.

Our conclusion on the Statement is not modified in respect of the above matters.

For **KARVY & CO**
Chartered Accountants
(Firm Registration No.001757S)


(AJAYKUMAR KOSARAJU)
P A R T N E R
M.No.021989
UDIN: 20021989AAAABK4405



Place: Hyderabad
Date: February 13, 2020

13/02/2020

News Release

Suven Pharmaceuticals Limited Revenue down by 34.05%; PAT down by 42.85% for quarter ended 31 December' 2019

HYDERABAD, INDIA (13 February, 2020) – Suven Pharmaceutical Limited (SPL), a company specialized in providing pharmaceutical solutions to global life science companies, today announced its Un-audited Financial Results for the quarter and nine months ended 31st December 2019. The Un-audited Financial Results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 13th February, 2020 at Hyderabad.

Post demerger of Suven Life Sciences Limited (SLSL), the resultant entity is SPL, continuing the operations of providing pharmaceuticals solutions to global life science companies. Post approval of Honorable National Company Law Tribunal (NCLT), the financials of SPL are separated 3rd quarter onwards from Suven Life Sciences. The below financial information relating to Suven Pharmaceutical Limited only.

Financial Highlights for the 3rd Quarter ended December' 2019 (QoQ):

Income	INR 1836 Mn vs 2784 Mn - down by 34.05%
PAT	INR 514 Mn vs 899 Mn – down by 42.85%
EBIDTA	INR 849 Mn vs 1310 Mn - down by 35.16%

The Board has declared an Interim Dividend of Re.2.50 per share (250% of face value of Rs. 1.00 each) and a one-time special dividend of Rs. 2.50 per share (250% of face value of RS. 1.00 each) totaling to Rs. 5.00 per share (500% of face value of Rs. 1.00 each) post demerger of Suven's CRAMS business.

For more details please visit www.suvenpharm.com and www.suven.com.

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

Suven Pharmaceuticals Limited

Registered Office: # 8-2-334 | SDE Serene Chambers | 3rd Floor | Road No.5

Avenue 7 | Banjara Hills | Hyderabad – 500034 | Telangana | India | CIN:U24299TG2018PLC128171

Tel: 91 40 2354 9414 /1142 /3311 | Fax: 91 40 2354 1152 | Email: info@suvenpharm.com | www.suvenpharm.com



Suven Pharmaceuticals Limited

Risk statement



Except for historical information, all the statements, expectations and assumptions, including expectations and assumptions contained in this presentation may be forward-looking statements that involve number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

13-Feb-20

2

Copyright © 2020 Suven Pharmaceuticals Limited

FINANCIAL QUICK VIEW



	FY 20 Q3 to Q2
Revenue	-34.05%
EBIDTA	-42.85%
PAT	-35.16%

Please note: The growth figures of 9 months are not comparable to previous year, as it involves 3 months, due to demerger appointed date being 1 Oct 2018.

13-Feb-20

MAJOR PROFITABILITY INDICATORS



	Q3 Dec 19	9 months- Dec 19
EBIDTA to Income	46.27%	48.44%
PAT to Income	27.98%	32.66%
EPS	2.71	17.04
Cash Flow to Income	31.25%	35.20%

13-Feb-20





4

Copyright © 2020 Suven Pharmaceuticals Limited

Q3 to Q2 COMPARISON



Current to previous quarter



13-Feb-20

FINANCIAL SNAPSHOT

All figures are in INR Million, other than ratios and EPS

	FY 20 Q3	FY 20 Q2	Growth %	FY 19 Q3	Growth %	FY 20 9 mons *
Income	1,835.94	2,783.73	-34.05%	1,271.01	44.45%	6,618.03
EBITDA	849.47	1,310.19	-35.16%	496.27	71.17%	3,205.66
EBITDA Margin	46.27%	47.07%		39.05%		48.44%
EBIT	783.23	1,253.69	-37.53%	441.87	77.26%	3,030.80
EBIT Margin	42.66%	45.04%		34.76%		45.80%
Financing costs	71.76	39.91		10.46		146.09
Taxes	197.74	314.89		86.90		723.11
Net Profit after tax	519.99	899.16	-42.17%	344.51	50.93%	2,168.40
NP Margin	28.32%	32.30%		27.11%		32.76%
EPS (basic & diluted not annualised)	4.09	7.06		2.71		17.04
Paid up share capital (One Rupee Share)	127.28	127.28		127.28		127.28

* Please note: The growth figures of 9 months are not comparable to previous year, as it involves 3 months, due to demerger appointed date being 1 Oct 2018.

Background info on demerger



- Suven Pharmaceuticals Limited (SPL), a company incorporated in November 2018, was a Wholly Owned Subsidiary of Suven Life Sciences Limited (SLSL), effective February 2019.
- SLSL, post the Board Meeting on February 5, 2019, announced demerger of SLSL into:
 - Suven Life Sciences Limited, the demerged entity, to continue innovative research focused on Central Nervous System (CNS) disorders to meet huge unmet global medical needs.
 - Suven Pharmaceuticals Limited, the resultant entity, to continue the pharmaceutical business operations.
- The Scheme of Arrangement has since been approved by the Hon'ble National Company Law Tribunal (NCLT), Hyderabad bench vide its order on dated 6th January 2020

Background info on demerger



- The Scheme, has become operative from the Appointed Date i.e., 1st October, 2018, but has become effective on 9th January, 2020 being the date on which certified copies of the Order of the NCLT, Hyderabad Bench sanctioning the Scheme was filed with the Registrar of Companies, Hyderabad, Telangana, both by the Demerged Company and Resulting Company.
- Having completed the demerger activities, the companies SPL and SLSL, has separated the accounts of each business entity. The financial results of the same has been presented from Q3 for each entity separately.
- Suven Pharmaceuticals Limited will be listed in stock exchanges in India and the is in progress.
- This presentation focus on financial results of Suven Pharmaceuticals Limited only.

8

News Release



- The Board has declared an Interim Dividend of Re.2.50 per share (250% of face value of Rs. 1.00 each) and a one-time special dividend of Rs. 2.50 per share (250% of face value of RS. 1.00 each) totaling to Rs. 5.00 per share (500% of face value of Rs. 1.00 each) post demerger of Suven's CRAMS business.

13-Feb-20

9

Copyright © 2020 Suven Pharmaceuticals Limited